Vad ca a continuat treaba juliana. In primul rand bine v-am regasit, La Multi ANi si sper ca totul e bine la toata lumea. Incepem un nou an, sper cu cat mai multe stiri bune si aparitii de medicamente miraculoase.
Pentru cine se intreba ce mai fac, sunt pe aici nu va faceti griji ca trec de cel putin 10 ori pe zi, insa eu prea multe neclaritati nu prea mai am, tot ce pot sa fac este sa mai ajut pe cineva cu sfaturi si o vorba buna.
http://archive.mail-list.com/hbv_research/msg09068.html
Un articol despre acelasi medicament Adefovir, se pare cel mai eficace pentru moment:
"Adefovir Dipivoxil Produces Sustained Improvement in HBV over Long Term:
Presented at HEP DART
By Bonnie Darves
KOHALA COAST, HI -- December 29, 2005 -- Patients with chronic hepatitis B
(HBV) who continue taking adefovir dipivoxil (ADV) for up to 5 years
continue to see improvements in hepatic fibrosis, HBV DNA suppression and
alanine aminotransferase (ALT) levels, with few adverse effects.
The new data on ADV were presented here at the Frontiers in Drug Development
for Viral Hepatitis HEP DART 2005 meeting.
"At 5 years the durability of this [therapy] is still greater than 91%, and
efficacy increased over time in all patient populations and disease stages,"
said presenter Carol Brosgart, MD, Vice President of Public Health and
Policy for the drug's maker, Gilead Sciences, Foster City, California,
United States.
In his presentation, Dr. Brosgart discussed long-term data on ADV, the first
of a new class of nucleotide analogues of adenosine monophosphate.
The study evaluated the drug in two primary groups of patients. The first
group included 123 treatment-na